AnaptysBio Inc (NASDAQ:ANAB) saw unusually large options trading activity on Wednesday. Investors acquired 1,126 call options on the stock. This represents an increase of approximately 924% compared to the average volume of 110 call options.
ANAB stock opened at $36.25 on Thursday. AnaptysBio has a twelve month low of $29.43 and a twelve month high of $87.49. The stock has a market capitalization of $915.56 million, a price-to-earnings ratio of -14.50 and a beta of 1.50. The firm’s fifty day simple moving average is $38.64 and its two-hundred day simple moving average is $57.96.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.97) by $0.08. The firm had revenue of $5.00 million for the quarter. During the same quarter last year, the business earned ($0.57) EPS. The firm’s revenue was up 4900.0% on a year-over-year basis. Equities research analysts forecast that AnaptysBio will post -4.13 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Aperio Group LLC bought a new position in shares of AnaptysBio in the second quarter worth about $45,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AnaptysBio by 30.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,298 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 306 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of AnaptysBio in the first quarter worth about $110,000. Bank of Montreal Can bought a new position in shares of AnaptysBio in the second quarter worth about $115,000. Finally, Jane Street Group LLC bought a new position in shares of AnaptysBio in the second quarter worth about $205,000.
Several brokerages recently weighed in on ANAB. SunTrust Banks reduced their price target on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Credit Suisse Group cut their price objective on shares of AnaptysBio from $75.00 to $48.00 and set a “neutral” rating on the stock in a research report on Thursday, October 3rd. Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, October 1st. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald set a $140.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a research report on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $99.63.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Article: Marijuana Stocks
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.